DBV Technologies CEO Announces Upcoming Biologics License Application Submissions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Should l Buy DBVT?
"The entire DBV team has been operating with exceptional focus and rigor as we progress towards significant milestones in the coming months, including the upcoming Biologics License Application (BLA) submissions for both our Children ages 4-7 and Toddler ages 1-3 programs in first half and second half of this year, respectively." said Daniel Tasse, Chief Executive Officer of DBV Technologies. "We also plan to initiate a first of its kind study in infants ages 6 through 12 months. This Phase 2 study, previously announced at last year's American College of Asthma, Allergy, and Immunology, and now called THRIVE, will assess the efficacy and safety of the VIASKIN(R) Peanut Patch in achieving ad lib consumption of dietary peanut in peanut-allergic infants 6 through 12 months of age following a minimum of 3 years of treatment. Across all development programs, we are operating with extreme precision and purpose with the goal of providing practical, non-invasive treatment options to peanut allergy families no matter where they are on their treatment journey."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DBVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DBVT
Wall Street analysts forecast DBVT stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.990
Low
40.00
Averages
46.40
High
51.00
Current: 19.990
Low
40.00
Averages
46.40
High
51.00
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DBV Technologies Reports Q1 Financial Results
- Financial Performance: DBV Technologies reported a Q1 GAAP EPS of -$0.11, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of March 31, 2026, the company held $229 million in cash and cash equivalents, an increase from $194 million on December 31, 2025, suggesting improvements in liquidity management.
- Operating Cash Usage: The net cash used for operating activities in Q1 was $49 million, significantly higher than $20 million in the same period of 2025, reflecting pressure on operational expenditures that may affect future funding operations.
- Financing Activities: The company generated $89 million in net cash flows from financing activities in Q1 2026, primarily due to the full exercise of ABSA and BS warrants, strengthening its capital base to support future growth.
See More
Total Voting Rights and Shares as of March 31, 2026
- Total Shares: As of March 31, 2026, the company has a total of 296,042,447 shares, reflecting stability in the market and a broad shareholder base, which may positively impact future financing and shareholder confidence.
- Total Voting Rights: The total number of voting rights on the same date is 296,042,447, indicating transparency in the company's governance structure and shareholder engagement, thereby enhancing investor trust in the decision-making process.
- Net Voting Rights: The net voting rights stand at 295,914,379, suggesting a small number of non-voting shares within the capital structure, which could affect shareholders' actual influence in significant decisions.
- Compliance Information: This disclosure complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers (AMF), ensuring the company's adherence to information disclosure regulations, which helps to build market trust in the company.
See More
DBV Tech Advances BLA Submission for VIASKIN Peanut Patch
- Application Progress: DBV Tech is advancing its Biologics License Application (BLA) for the VIASKIN peanut patch, marking a significant milestone in the treatment of allergies in children, which is expected to enhance its market competitiveness.
- Analyst Rating: Analysts maintain a 'Buy' rating on DBV Tech with a target price of $51, reflecting positive market expectations regarding the product's potential, which may attract more investor interest.
- Market Outlook: The VIASKIN peanut patch represents an innovative therapy aimed at providing safe and effective allergy treatment for children, and if approved, it will help the company secure a position in the rapidly growing allergy treatment market.
- Strategic Implications: By advancing the BLA submission, DBV Tech not only demonstrates its R&D capabilities but also potentially lays the groundwork for future product line expansions, thereby enhancing overall business growth potential.
See More
DBV Technologies Releases FY 2025 Financial Results
- Financial Performance: DBV Technologies reported a GAAP EPS of -$1.05 for FY 2025, indicating ongoing challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, DBV held $194.2 million in cash and cash equivalents, a significant increase from $32.5 million in 2024, reflecting improved cash management practices.
- Operating Cash Usage: The net cash used for operating activities was $121.2 million in 2025 compared to $104.5 million in 2024, highlighting that despite increased cash reserves, high operational expenditures remain a significant financial pressure for the company.
- Industry Engagement: DBV Technologies is set to present at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting, indicating active participation in the industry that may pave the way for future collaborations and funding opportunities.
See More
DBV Technologies Files 2025 Annual Report and URD
- Annual Report Filing: On March 26, 2026, DBV Technologies filed its 2025 Annual Report on Form 10-K with the SEC and its Universal Registration Document (URD) with the AMF, ensuring compliance and enhancing transparency for investors.
- Compliance Disclosure: The 2025 URD includes the annual financial report, corporate governance report, share buy-back program description, and statutory auditor reports, fulfilling the requirements of Article L. 225-37 of the French Commercial Code, thereby boosting investor confidence.
- Focus on Allergy Treatment: DBV Technologies is dedicated to developing treatment options for food allergies, particularly through its proprietary VIASKIN® patch technology, which aims to introduce microgram amounts of biologically active compounds through the skin to retrain the immune system, addressing significant unmet medical needs in the market.
- Clinical Trial Progress: The company is currently conducting clinical trials of the VIASKIN® Peanut Patch for food-allergic toddlers and children aged 1 to 7, demonstrating potential in alleviating allergy symptoms and further solidifying DBV Technologies' market position in the biopharmaceutical sector.
See More
DBV Technologies to Participate in March Investor Conferences
- Investor Conference Schedule: DBV Technologies will participate in two key investor conferences in March 2026, namely the Citizens Life Sciences Conference on March 10 and the Leerink Partners Global Healthcare Conference on March 11, showcasing its latest advancements in food allergy treatments.
- Innovative Technology Introduction: The company focuses on developing its proprietary VIASKIN® patch technology, designed to introduce microgram amounts of biologically active compounds through the skin via epicutaneous immunotherapy (EPIT), aiming to re-educate the immune system and potentially transform the market.
- Clinical Trial Progress: DBV Technologies is conducting clinical trials for the VIASKIN Peanut patch targeting peanut-allergic toddlers and children aged 1 to 7, demonstrating the company's commitment to addressing significant unmet medical needs and potentially offering new treatment options for millions of allergy sufferers.
- Market Positioning and Development: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on the Nasdaq Capital Market, reflecting its strategic positioning in the global market.
See More
DBV Technologies Reports Q1 Financial Results
- Financial Performance: DBV Technologies reported a Q1 GAAP EPS of -$0.11, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of March 31, 2026, the company held $229 million in cash and cash equivalents, an increase from $194 million on December 31, 2025, suggesting improvements in liquidity management.
- Operating Cash Usage: The net cash used for operating activities in Q1 was $49 million, significantly higher than $20 million in the same period of 2025, reflecting pressure on operational expenditures that may affect future funding operations.
- Financing Activities: The company generated $89 million in net cash flows from financing activities in Q1 2026, primarily due to the full exercise of ABSA and BS warrants, strengthening its capital base to support future growth.
See More
Total Voting Rights and Shares as of March 31, 2026
- Total Shares: As of March 31, 2026, the company has a total of 296,042,447 shares, reflecting stability in the market and a broad shareholder base, which may positively impact future financing and shareholder confidence.
- Total Voting Rights: The total number of voting rights on the same date is 296,042,447, indicating transparency in the company's governance structure and shareholder engagement, thereby enhancing investor trust in the decision-making process.
- Net Voting Rights: The net voting rights stand at 295,914,379, suggesting a small number of non-voting shares within the capital structure, which could affect shareholders' actual influence in significant decisions.
- Compliance Information: This disclosure complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers (AMF), ensuring the company's adherence to information disclosure regulations, which helps to build market trust in the company.
See More
DBV Tech Advances BLA Submission for VIASKIN Peanut Patch
- Application Progress: DBV Tech is advancing its Biologics License Application (BLA) for the VIASKIN peanut patch, marking a significant milestone in the treatment of allergies in children, which is expected to enhance its market competitiveness.
- Analyst Rating: Analysts maintain a 'Buy' rating on DBV Tech with a target price of $51, reflecting positive market expectations regarding the product's potential, which may attract more investor interest.
- Market Outlook: The VIASKIN peanut patch represents an innovative therapy aimed at providing safe and effective allergy treatment for children, and if approved, it will help the company secure a position in the rapidly growing allergy treatment market.
- Strategic Implications: By advancing the BLA submission, DBV Tech not only demonstrates its R&D capabilities but also potentially lays the groundwork for future product line expansions, thereby enhancing overall business growth potential.
See More
DBV Technologies Releases FY 2025 Financial Results
- Financial Performance: DBV Technologies reported a GAAP EPS of -$1.05 for FY 2025, indicating ongoing challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, DBV held $194.2 million in cash and cash equivalents, a significant increase from $32.5 million in 2024, reflecting improved cash management practices.
- Operating Cash Usage: The net cash used for operating activities was $121.2 million in 2025 compared to $104.5 million in 2024, highlighting that despite increased cash reserves, high operational expenditures remain a significant financial pressure for the company.
- Industry Engagement: DBV Technologies is set to present at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting, indicating active participation in the industry that may pave the way for future collaborations and funding opportunities.
See More
DBV Technologies Files 2025 Annual Report and URD
- Annual Report Filing: On March 26, 2026, DBV Technologies filed its 2025 Annual Report on Form 10-K with the SEC and its Universal Registration Document (URD) with the AMF, ensuring compliance and enhancing transparency for investors.
- Compliance Disclosure: The 2025 URD includes the annual financial report, corporate governance report, share buy-back program description, and statutory auditor reports, fulfilling the requirements of Article L. 225-37 of the French Commercial Code, thereby boosting investor confidence.
- Focus on Allergy Treatment: DBV Technologies is dedicated to developing treatment options for food allergies, particularly through its proprietary VIASKIN® patch technology, which aims to introduce microgram amounts of biologically active compounds through the skin to retrain the immune system, addressing significant unmet medical needs in the market.
- Clinical Trial Progress: The company is currently conducting clinical trials of the VIASKIN® Peanut Patch for food-allergic toddlers and children aged 1 to 7, demonstrating potential in alleviating allergy symptoms and further solidifying DBV Technologies' market position in the biopharmaceutical sector.
See More
DBV Technologies to Participate in March Investor Conferences
- Investor Conference Schedule: DBV Technologies will participate in two key investor conferences in March 2026, namely the Citizens Life Sciences Conference on March 10 and the Leerink Partners Global Healthcare Conference on March 11, showcasing its latest advancements in food allergy treatments.
- Innovative Technology Introduction: The company focuses on developing its proprietary VIASKIN® patch technology, designed to introduce microgram amounts of biologically active compounds through the skin via epicutaneous immunotherapy (EPIT), aiming to re-educate the immune system and potentially transform the market.
- Clinical Trial Progress: DBV Technologies is conducting clinical trials for the VIASKIN Peanut patch targeting peanut-allergic toddlers and children aged 1 to 7, demonstrating the company's commitment to addressing significant unmet medical needs and potentially offering new treatment options for millions of allergy sufferers.
- Market Positioning and Development: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on the Nasdaq Capital Market, reflecting its strategic positioning in the global market.
See More
